Evidence map›Paper›PMID 39830623›Full record

ArticleCurrent opinion in biomedical engineering2022

Bioresorbable vascular metallic scaffolds: Current status and research trends.

Jaroslaw W Drelich, Jeremy Goldman

Abstract read
In one paragraph

Article in Current opinion in biomedical engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Thrombogenicity of biodegradable metals.Bioactive materials · 2024
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jaroslaw W DrelichDepartment of Materials Science and Engineering, Michigan Technological University, Houghton, MI, 49931, USA.
Jeremy GoldmanDepartment of Biomedical Engineering, Michigan Technological University, Houghton, MI, 49931, USA.

Funding

Corrosion Fatigue Resistant and Intimal Hyperplasia Suppressive Biometal for Bioabsorbable StentsR01HL144739 · NHLBI · MICHIGAN TECHNOLOGICAL UNIVERSITY · PI DRELICH, JAROSLAW W · 2019 to 2021
$1.1M
NHLBI NIH HHS R01 HL144739
6 · The paper itself

Abstract

To combat the long-term side effects associated with present-generation drug-eluting stents and provide opportunities for repeat scaffolding of plaqued arteries and treatment of coarctation of the aorta in infants and children, a new generation of bioresorbable stents has been introduced. Stents made of bioresorbable materials are corroded and absorbed by the body after completing their task as vascular scaffolding, allowing the stented arteries to restore their normal function. The concept is achieved by engineering stents that retain mechanical properties and integrity for at least 6-12 months before being broken down, metabolized, and harmlessly excreted by the body, leaving the treated vessel with a healthy endothelium, normal vasomotion, and free of the implant. In this article, the authors briefly review the development status of bioresorbable materials for stenting applications, their mechanical properties, and behavior in the vascular environment. Emphasis is given to new materials and under-explored research directions including long-term biocompatibility and emerging designs of bioactive stents. The goal for next-generation bioresorbable metals is the controlled release of therapeutic metal ions that could eliminate the need for anti-inflammatory drug-eluting coatings, characteristic of current-generation biostable stent metal scaffolds.

Indexed as

Bioresorbable scaffoldsIron alloysMagnesium alloysMolybdenumZinc alloys

Identifiers

PMID39830623
PMCPMC11741677

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.